Literature DB >> 15123266

Novel heparan sulfate mimetic compounds as antitumor agents.

Keisuke Ishida1, Michal K Wierzba, Takayuki Teruya, Siro Simizu, Hiroyuki Osada.   

Abstract

Heparan sulfate glycosaminoglycans (HSGAGs) are involved in tumor cell growth, adhesion, invasion, and migration, due to their interactions with various proteins. In this study, novel HSGAG-mimetic compounds (KI compounds) were designed and synthesized. As a result of cell-based assays, KI-105 was found to exert potent inhibitory activities against migration and invasion of human fibrosarcoma HT1080 cells. The present results indicate that a novel invasion/migration inhibitor, KI-105, can increase the adherence of HT1080 cells. It was conceivable that this cellular effect was caused by an increase in the amount of cell-surface HSGAGs and focal adhesions. Although further investigations are needed to decipher the molecular mechanism of KI-105, it is suggested that heparanase and Cdc42 are involved in its biological effects.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15123266     DOI: 10.1016/j.chembiol.2004.02.015

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  10 in total

1.  Inhibitors of slit protein interactions with the heparan sulphate proteoglycan glypican-1: potential agents for the treatment of spinal cord injury.

Authors:  Elizabeth Lau; Richard U Margolis
Journal:  Clin Exp Pharmacol Physiol       Date:  2009-10-16       Impact factor: 2.557

2.  Small molecule targeting malaria merozoite surface protein-1 (MSP-1) prevents host invasion of divergent plasmodial species.

Authors:  Rajesh Chandramohanadas; Bruce Russell; Kingsley Liew; Yin Hoe Yau; Alvin Chong; Min Liu; Karthigayan Gunalan; Rahul Raman; Laurent Renia; Francois Nosten; Susana Geifman Shochat; Ming Dao; Ram Sasisekharan; Subra Suresh; Peter Preiser
Journal:  J Infect Dis       Date:  2014-05-26       Impact factor: 5.226

3.  Heparin-mimetic sulfated peptides with modulated affinities for heparin-binding peptides and growth factors.

Authors:  Sung Hye Kim; Kristi L Kiick
Journal:  Peptides       Date:  2007-08-19       Impact factor: 3.750

4.  Heparan sulfate mimetic PG545-mediated antilymphoma effects require TLR9-dependent NK cell activation.

Authors:  Todd V Brennan; Liwen Lin; Joshua D Brandstadter; Victoria R Rendell; Keith Dredge; Xiaopei Huang; Yiping Yang
Journal:  J Clin Invest       Date:  2015-12-07       Impact factor: 14.808

Review 5.  Roles of glycosaminoglycans and glycanmimetics in tumor progression and metastasis.

Authors:  Kanchugarakoppal S Rangappa; Kazuyuki Sugahara
Journal:  Glycoconj J       Date:  2014-10       Impact factor: 2.916

6.  Characterization of a κ-carrageenase from marine Cellulophaga lytica strain N5-2 and analysis of its degradation products.

Authors:  Ziang Yao; Feifei Wang; Zheng Gao; Liming Jin; Haige Wu
Journal:  Int J Mol Sci       Date:  2013-12-17       Impact factor: 5.923

7.  Cell-dependent regulation of vasculogenic mimicry by carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1).

Authors:  Soichiro Hayashi; Yoshiyuki Osada; Kazuki Miura; Siro Simizu
Journal:  Biochem Biophys Rep       Date:  2020-01-30

8.  Methionine aminopeptidase‑2 is a pivotal regulator of vasculogenic mimicry.

Authors:  Shota Shimizu; Ryota Kawahara; Siro Simizu
Journal:  Oncol Rep       Date:  2021-12-16       Impact factor: 3.906

9.  Anti-tumor activity of a novel HS-mimetic-vascular endothelial growth factor binding small molecule.

Authors:  Kazuyuki Sugahara; Kuntebommanahalli N Thimmaiah; Hemant K Bid; Peter J Houghton; Kanchugarakoppal S Rangappa
Journal:  PLoS One       Date:  2012-08-15       Impact factor: 3.240

Review 10.  The Role of Heparanase and Sulfatases in the Modification of Heparan Sulfate Proteoglycans within the Tumor Microenvironment and Opportunities for Novel Cancer Therapeutics.

Authors:  Edward Hammond; Ashwani Khurana; Viji Shridhar; Keith Dredge
Journal:  Front Oncol       Date:  2014-07-24       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.